Venovenous extracorporeal membrane oxygenation for respiratory failure in inotrope dependent neonates.
It is often stated that venovenous extracorporeal membrane oxygenation (VV ECMO) should not be used in inotrope dependent patients. It is our practice to use VV ECMO in most patients with respiratory failure even though many of these patients are receiving significant doses of inotropes. Our objective was to review the mode of ECMO in relation to precannulation doses of inotropes administered to neonates treated with ECMO for respiratory failure. Forty-three consecutive case notes were reviewed. Data were collected for basic demographic and ECMO parameters. Inotropic doses were converted to a single score for ease of comparison, with one point equivalent to 1 microg/kg/min dopamine. Forty-three neonates were studied; 37(86%) were treated with VV ECMO and 6 (14%) were treated with VA ECMO. Significant pre-ECMO inotropic support (score > 10) was present in 30 (70%) of the 43 cases. Of these patients, 26 were treated via VV ECMO with a survival rate of 84%, while 4 were treated with VA ECMO with a survival of 75%. Inotrope scores fell to nonsignificant levels (< 10) within 24 hours, regardless of ECMO mode. Mean arterial blood pressure remained above precannulation levels in both groups. VV ECMO allows safe treatment of neonatal respiratory failure in the presence of significant inotropic support. We recommend VV ECMO for neonatal respiratory failure in all cases except where double lumen cannulation is impossible or when septic shock is refractory to inotropic support (i.e., mean blood pressure < 35 mm Hg despite inotrope score of > 100).
Roberts
Neil
N
Heartlink ECMO Centre, Glenfield Hospital, Groby Road, Leicester LE3 9QQ, United Kingdom.
Westrope
Claire
C
Pooboni
Suneel K
SK
Mulla
Hussain
H
Peek
Giles J
GJ
Sosnowski
Andrew W
AW
Firmin
Richard K
RK
D001794:Blood Pressure; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004298:Dopamine / Q000627:therapeutic use*; D004837:Epinephrine / Q000627:therapeutic use; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D007231:Infant, Newborn; D009638:Norepinephrine / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D013566:Sympathomimetics / Q000627:therapeutic use
D002316:Cardiotonic Agents; D013566:Sympathomimetics; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine